To explore this possibility, we investigated whether the parecoxib/5-FU combination exhibits a superior ability to modulate the PI3K/Akt/NF-κB signaling pathways for promoting antimetastatic activity in human colorectal cancer. This evidence concerns the gene AKT1 and colorectal cancer.